- Home
- LITE vs AXSM Comparison
LITE vs AXSM Comparison
Compare LITE & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITE
- AXSM
- Stock Information
- Founded
- LITE 2015
- AXSM 2012
- Country
- LITE United States
- AXSM United States
- Employees
- LITE N/A
- AXSM N/A
- Industry
- LITE Telecommunications Equipment
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- LITE Telecommunications
- AXSM Health Care
- Exchange
- LITE Nasdaq
- AXSM Nasdaq
- Market Cap
- LITE N/A
- AXSM 4.0B
- IPO Year
- LITE N/A
- AXSM 2015
- Fundamental
- Price
- LITE $50.87
- AXSM $93.61
- Analyst Decision
- LITE Buy
- AXSM Strong Buy
- Analyst Count
- LITE 13
- AXSM 14
- Target Price
- LITE $59.08
- AXSM $124.57
- AVG Volume (30 Days)
- LITE 2.0M
- AXSM 412.8K
- Earning Date
- LITE 11-06-2024
- AXSM 11-04-2024
- Dividend Yield
- LITE N/A
- AXSM N/A
- EPS Growth
- LITE N/A
- AXSM N/A
- EPS
- LITE N/A
- AXSM N/A
- Revenue
- LITE $1,359,200,000.00
- AXSM $291,489,000.00
- Revenue This Year
- LITE $13.52
- AXSM $42.50
- Revenue Next Year
- LITE $29.55
- AXSM $69.28
- P/E Ratio
- LITE N/A
- AXSM N/A
- Revenue Growth
- LITE N/A
- AXSM 59.73
- 52 Week Low
- LITE $35.35
- AXSM $55.02
- 52 Week High
- LITE $60.99
- AXSM $98.40
- Technical
- Relative Strength Index (RSI)
- LITE 44.95
- AXSM 62.17
- Support Level
- LITE $50.60
- AXSM $91.52
- Resistance Level
- LITE $58.01
- AXSM $96.56
- Average True Range (ATR)
- LITE 2.44
- AXSM 2.81
- MACD
- LITE -0.62
- AXSM 0.37
- Stochastic Oscillator
- LITE 0.17
- AXSM 62.51
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.